FDA Panel Mulls Clinical Studies, Labeling For Over-The-Counter HIV Tests
This article was originally published in The Gray Sheet
Executive Summary
Over-the-counter (OTC) HIV test kits would answer an unmet need, but clinical trials and product labeling must be carefully crafted to ensure that benefits outweigh the risks, according to FDA's Blood Products Advisory Committee
You may also be interested in...
OraSure Over-The-Counter HIV Test: Complete PMA Filing Planned By Year End
OraSure Technologies expects to complete a PMA filing for its OraQuick Advance rapid HIV-1 and -2 over-the-counter saliva test by the end of the year.
OraSure Over-The-Counter HIV Test: Complete PMA Filing Planned By Year End
The application will be submitted in three parts to give FDA more time to absorb the vast trove of information and potentially speed up the process, CEO Michels said.
OraSure Over-The-Counter HIV Test: Complete PMA Filing Planned By Year End
OraSure Technologies expects to complete a PMA filing for its OraQuick Advance rapid HIV-1 and -2 over-the-counter saliva test by the end of the year.